<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ano5-md" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ano5-md</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">ANO5</italic>-Related Muscle Diseases</title>
        <alt-title alt-title-type="alt-title">Synonym: Anoctaminopathy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Penttil&#x000e4;</surname>
            <given-names>Sini</given-names>
          </name>
          <degrees>MSc</degrees>
          <email>sini.penttila@uta.fi</email>
          <aff>Neuromuscular Research Unit<break/>University of Tampere<break/>Tampere, Finland</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Palmio</surname>
            <given-names>Johanna</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>johanna.palmio@uta.fi</email>
          <aff>Neuromuscular Research Unit<break/>University of Tampere<break/>Tampere, Finland</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Udd</surname>
            <given-names>Bjarne</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>Bjarne.Udd@pshp.fi</email>
          <aff>Neuromuscular Research Unit<break/>University of Tampere<break/>Tampere, Finland</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2012-11-29" date-type="created">
          <day>29</day>
          <month>11</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="iahsp" document-type="chapter">
<italic toggle="yes">ALS2</italic>-Related Disorders</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="fap" document-type="chapter"><italic toggle="yes">APC</italic>-Associated Polyposis Conditions</related-object>
      <abstract id="ano5-md.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The spectrum of <italic toggle="yes">ANO5</italic>-related muscle diseases is a continuum that ranges from asymptomatic hyperCKemia and exercise-induced myalgia to proximal and/or distal muscle weakness. The most typical presentation is limb-girdle muscular dystrophy type 2L (LGMD2L) with late-onset proximal lower-limb weakness (mean onset age 35 years; range 15-70 years). Less common is Miyoshi-like disease or Miyoshi muscular dystrophy 3 with early adult-onset calf distal myopathy (age 20 to 25 years). Incidental hyperCKemia may be present even earlier. Females have milder disease manifestations than males. Initial symptoms are walking difficulties, reduced sports performance, and difficulties in standing on toes as well as nonspecific exercise myalgia and/or burning sensation in the calf muscles. Muscle weakness and atrophy are frequently asymmetric. Bulbar or respiratory symptoms have not been reported. Disease progression is slow in both the LGMD and distal forms; ambulation is preserved until very late in the disease course. </p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis is based on clinical findings, elevated serum CK concentration, and molecular genetic testing of <italic toggle="yes">ANO5.</italic></p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> No definitive treatments for the limb-girdle muscular dystrophies exist. Management is tailored to the individual. To prolong survival and improve quality of life the following are suggested: weight control to avoid obesity, physical therapy and stretching exercises to promote mobility and prevent contractures, and use of mechanical aids to help ambulation and mobility. The need for orthoses or other assistive devices varies individually; hyperextension of the knee can be treated by splinting.</p>
          <p><italic toggle="yes">Surveillance:</italic> For persons with muscle weakness: evaluate muscle strength and functional status every six to 12 months. For asymptomatic persons: evaluate less frequently.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Heavy muscle force training of weak muscles. The use of statins, which can induce muscle pain and worsen muscle weakness, requires extra monitoring of clinical status especially at the beginning of treatment. </p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">ANO5</italic>-related muscle diseases are inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the disease-causing mutations in the family have been identified. Requests for prenatal testing for conditions such as the <italic toggle="yes">ANO5</italic>-related muscle diseases that do not affect intellect and are typically adult onset are not common. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ano5-md.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="ano5-md.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ano5-md.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">ANO5</italic>-Related Muscle Diseases: Included Disorders</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ano5-md.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Limb-Girdle muscular dystrophy type 2L </p>
                    </list-item>
                    <list-item>
                      <p>Miyoshi muscular dystrophy 3</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="ano5-md.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="ano5-md.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ano5-md.Clinical_Diagnosis">
          <title>Clinical Diagnosis </title>
          <p>The spectrum of <italic toggle="yes">ANO5</italic>-related muscle diseases is a continuum that ranges from asymptomatic hyperCKemia and exercise-induced myalgia to proximal and/or distal muscle weakness. The most typical presentation is limb-girdle muscular dystrophy type 2L (LGMD2L) with late-onset proximal lower-limb weakness (mean onset age 35 years; range 15-70 years) [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>]. Less common is Miyoshi-like disease or Miyoshi muscular dystrophy 3 with early adult-onset calf distal myopathy (age 20 to 25 years) [<xref ref-type="bibr" rid="ano5-md.REF.mahjneh.2010.791">Mahjneh et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
          <p>Adult-onset, asymmetric muscle weakness and atrophy, especially in thigh muscles, are characteristic features in ANO5-related muscle diseases (<xref ref-type="fig" rid="ano5-md.F1">Figure 1</xref>).</p>
          <p>Females are generally less severely affected than males [<xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>]. </p>
          <p><bold>EMG</bold> reveals myopathic changes with scattered necrotic fibers; however, it can be normal in mildly affected individuals [<xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
          <p><bold>CT and MRI</bold> show fatty degeneration of the gastrocnemius medialis muscle in most affected individuals. As the disease progresses, the soleus and posterior thigh muscles are frequently involved (<xref ref-type="fig" rid="ano5-md.F2">Figure 2</xref>) [<xref ref-type="bibr" rid="ano5-md.REF.mahjneh.2010.791">Mahjneh et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.magri.2012.934">Magri et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
        </sec>
        <sec id="ano5-md.Testing">
          <title>Testing</title>
          <p><bold>Serum CK concentration</bold> is markedly elevated (&#x02265;2-3x &#x02013; and usually 10-50x &#x02013; the upper limit of normal). Although serum CK concentration may vary between measurements in the same individual, normal concentrations have not been reported, even in the elderly. </p>
          <p><bold>Muscle biopsy</bold> shows scattered necrotic fibers or nonspecific myopathic or dystrophic findings [<xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
          <sec id="ano5-md.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing </title>
            <p><bold>Gene.</bold>
<italic toggle="yes">ANO5</italic> is the only gene in which mutations are known to cause <italic toggle="yes">ANO5</italic>-related muscle diseases. </p>
            <table-wrap id="ano5-md.T.summary_of_molecular_genetic_t" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">ANO5</italic>-Related Muscle Diseases</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutations Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">ANO5</italic>
                    </td>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exonic or whole-gene deletions </td>
                    <td headers="hd_h_ano5-md.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown; none reported&#x000a0;<sup>8</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ano5-md.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ano5-md" object-id="ano5-md.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="ano5-md.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="ano5-md.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ano5-md.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a mutation that is present in the indicated gene</p>
                </fn>
                <fn id="ano5-md.TF.1.4">
                  <label>4. </label>
                  <p>Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>. </p>
                </fn>
                <fn id="ano5-md.TF.1.5">
                  <label>5. </label>
                  <p>The most common mutations in northern European populations are <xref ref-type="table" rid="ano5-md.T.selected_ano5_allelic_variants">c.191dupA</xref> in exon 5 and <xref ref-type="table" rid="ano5-md.T.selected_ano5_allelic_variants">c.2272C&#x0003e;T</xref> in exon 20. To date, in publications of <italic toggle="yes">ANO5</italic>-related muscle diseases in persons of European origin, sequence analysis of exons 5 and 20 reveals at least one mutation in the majority (45/53) [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.bouquet.2012.135">Bouquet et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.magri.2012.934">Magri et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.milone.2012.13">Milone et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.schessl.2012.740">Schessl et al 2012</xref>]. Detecting the other mutation often requires sequence analysis of the whole gene.</p>
                </fn>
                <fn id="ano5-md.TF.1.6">
                  <label>6. </label>
                  <p>Sequence analysis of all the exons and exon-intron regions detects all reported mutations [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.deschauer.2011.1596">Deschauer et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.magri.2012.934">Magri et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.milone.2012.13">Milone et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.schessl.2012.740">Schessl et al 2012</xref>]. It is unknown if there are mutations that cannot be detected by sequence analysis.</p>
                </fn>
                <fn id="ano5-md.TF.1.7">
                  <label>7. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="ano5-md.TF.1.8">
                  <label>8. </label>
                  <p>No deletions or duplications of <italic toggle="yes">ANO5</italic> have been reported to cause limb-girdle muscular dystrophy type 2L. </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="ano5-md.Testing_Strategy">
          <title>Testing Strategy </title>
          <p><bold>To confirm/establish the diagnosis in a proband</bold> with findings suggestive of <italic toggle="yes">ANO5</italic>-related muscle diseases, perform molecular genetic testing. Two strategies are: </p>
          <p><bold>Single-gene testing</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">ANO5</italic> exons 5 and 20. In persons of northern and central European ancestry, the most common <italic toggle="yes">ANO5</italic> mutations are c.191dupA in exon 5 and c.2272C&#x0003e;T in exon 20. For these individuals sequence analysis of these two exons usually reveals at least one mutation.</p>
            </list-item>
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">ANO5</italic>. Among persons of other than northern and central European ancestry the c.191dupA and c.2272C&#x0003e;T mutations may be less common; therefore, for these individuals sequence analysis of the entire gene is the preferred approach to molecular genetic testing [<xref ref-type="bibr" rid="ano5-md.REF.magri.2012.934">Magri et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.schessl.2012.740">Schessl et al 2012</xref>].</p>
            </list-item>
          </list>
          <p><bold>Multi-gene testing</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Because the limb-girdle muscular dystrophy (LGMD) phenotype of <italic toggle="yes">ANO5</italic>-related muscle diseases may not be distinguishable from LGMD caused by mutations in other genes, clinicians may consider using a multi-gene limb-girdle muscular dystrophy panel that includes <italic toggle="yes">ANO5</italic>. Note that multi-gene panels vary by methods used and genes included; thus, the ability of a panel to detect a causative mutation(s) in any given individual also varies. </p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the disease-causing mutations in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the disease-causing mutations in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the disease-causing mutations in the family.</p>
        </sec>
      </sec>
      <sec id="ano5-md.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="ano5-md.Natural_History">
          <title>Clinical Description</title>
          <p>The spectrum of <italic toggle="yes">ANO5</italic>-related muscle diseases is a continuum ranging from asymptomatic hyperCKemia and exercise-induced myalgia to proximal and/or distal muscle weakness. The most typical presentation is late-onset proximal lower-limb weakness (also called limb-girdle muscular dystrophy type 2L) [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>] (<xref ref-type="table" rid="ano5-md.T.the_lgmd2l_phenotype">Table 2</xref>). Less common is early adult-onset calf distal myopathy (also called Miyoshi muscular dystrophy 3) [<xref ref-type="bibr" rid="ano5-md.REF.mahjneh.2010.791">Mahjneh et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
          <p>Females have milder disease manifestations than males [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.magri.2012.934">Magri et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>]. </p>
          <p>Onset of the proximal weakness in the limb-girdle muscular dystrophy (LGMD) form is in the fourth or fifth decade (age range 15-70 years); onset of calf weakness in the distal form is around age 20 years. Incidental hyperCKemia may be present even earlier. Initial symptoms are walking difficulties, reduced sports performance, and difficulties in standing on toes as well as nonspecific exercise myalgia and/or burning sensation in the calf muscles [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
          <p>In the limb-girdle muscular dystrophy form, muscle weakness is mainly proximal and more pronounced in the lower limbs; however, many affected individuals also have proximal upper-limb involvement. </p>
          <p>In the distal myopathy form, calf hypertrophy and exercise myalgia can occur before apparent weakness and later calf atrophy. Clinical manifestations can be mild or subjectively nonexistent even with clear changes observed on muscle imaging. Individuals with distal onset may have proximal lower-limb weakness in the later stages of the disease. Distal upper-limb weakness has not been reported. </p>
          <p>In most affected males muscle weakness is apparent with variable severity whereas in affected females the symptoms are consistently milder. Of 17 affected females reported to date, only five have had detectable muscle weakness and the others have had only hyperCKemia with or without myalgia [<xref ref-type="bibr" rid="ano5-md.REF.bolduc.2010.213">Bolduc et al 2010</xref>, <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>, <xref ref-type="bibr" rid="ano5-md.REF.magri.2012.934">Magri et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.milone.2012.13">Milone et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.schessl.2012.740">Schessl et al 2012</xref>]. </p>
          <p>Muscle weakness and atrophy are frequently asymmetric (<xref ref-type="fig" rid="ano5-md.F1">Figure 1</xref>).</p>
          <table-wrap id="ano5-md.T.the_lgmd2l_phenotype" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>The LGMD2L Phenotype </p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Clinical Characteristic</th>
                  <th id="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1"># of Individuals</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Increased creatine kinase value (&#x0003e;10x)</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Proximal lower-limb weakness</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Adult onset (&#x0003e;20 years)</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">19/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Muscle atrophy:</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">19/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Quadriceps/hamstrings</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">15/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Calf</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">14 (8&#x000a0;<sup>1</sup>) /20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Quadriceps/hamstrings and calf</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">10/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Upper-limb (mainly biceps)</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">7/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Asymmetry of muscle weakness or atrophy</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">18/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Distal lower-limb weakness:</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">17/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Mild</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">13/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Moderate to severe</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">5/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Upper-limb proximal weakness:</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">13/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Mild</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">11/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Moderate to severe</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Good sports performance in presymptomatic period</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">8/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Knee hyperextension</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">7/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Scapular winging</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Restriction/loss of ambulation</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">4/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Contractures</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">4/20</td>
                </tr>
                <tr>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Myoglobinuria</td>
                  <td headers="hd_h_ano5-md.T.the_lgmd2l_phenotype_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3/20</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>From <xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al [2011]</xref></p>
              </fn>
              <fn id="ano5-md.TF.2.1">
                <label>1. </label>
                <p>Medial part</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>In 19 individuals with <italic toggle="yes">ANO5</italic>-related muscle diseases who underwent systematic cardiac investigations, two had dilated cardiomyopathy and three had left ventricular dilatation [<xref ref-type="bibr" rid="ano5-md.REF.wahbi.2013.76">Wahbi et al 2013</xref>]. Bulbar or respiratory symptoms have not been reported. </p>
          <p>Disease progression is slow in both the LGMD and distal form; ambulation is preserved until very late in the disease course. Most affected individuals remain ambulatory without assistance for decades. Life span appears to be normal.</p>
        </sec>
        <sec id="ano5-md.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations </title>
          <p>Although genotype-phenotype correlations were initially suggested, no correlations were detected in a large patient cohort [<xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>].</p>
        </sec>
        <sec id="ano5-md.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance of disease manifestations in those with biallelic <italic toggle="yes">ANO5</italic> mutations depends on the clinical findings used to determine presence of clinical manifestations, age, and sex.</p>
          <p>In early stages of the disease (before evidence of subclinical findings on muscle MRI of the disease), hyperCKemia may be the only sign of the disease. </p>
          <p>Based on subclinical findings on muscle imaging in affected individuals in the families studied to date, the penetrance in those with biallelic confirmed pathogenic mutations is complete; however, expressivity is variable as the age of onset varies significantly, and females, who are less severely affected than males, may remain symptom free at a later age than males [<xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>]. </p>
        </sec>
        <sec id="ano5-md.Anticipation">
          <title>Anticipation </title>
          <p>Anticipation is not known to occur in <italic toggle="yes">ANO5</italic>-related muscle diseases.</p>
        </sec>
        <sec id="ano5-md.Nomenclature">
          <title>Nomenclature</title>
          <p>Miyoshi muscular dystrophy 3 may also be referred to as non-dysferlin Miyoshi muscular dystrophy or MMD3. </p>
        </sec>
        <sec id="ano5-md.Prevalence">
          <title>Prevalence </title>
          <p><italic toggle="yes">ANO5</italic>-related muscle diseases have been estimated to be one of the most common causes of limb-girdle muscular dystrophy. Prevalence in Finland is as high as 2:100,000 [<xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>]; in the North of England it has been estimated at 0.26:100,000 [<xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>]. </p>
        </sec>
      </sec>
      <sec id="ano5-md.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders </title>
        <p>Dominant mutations in <italic toggle="yes">ANO5</italic> are known to cause gnathodiaphyseal dysplasia. To date only three dominant mutations have been reported [<xref ref-type="bibr" rid="ano5-md.REF.tsutsumi.2004.1255">Tsutsumi et al 2004</xref>, <xref ref-type="bibr" rid="ano5-md.REF.marconi.2013.613">Marconi et al 2013</xref>]. Two of the mutations, c.1066T&#x0003e;C (p.Cys356Arg) and c.1066T&#x0003e;G (p.Cys356Gly), affect the same evolutionarily conserved amino acid, whereas the third mutation c.1538C&#x0003e;T (p.Thr513Ile) has a lower degree of conservation. The functional difference between dominant and recessive <italic toggle="yes">ANO5</italic> mutations is not understood.</p>
      </sec>
      <sec id="ano5-md.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Limb-girdle muscular dystrophy.</bold> The differential diagnosis of <italic toggle="yes">ANO5-</italic>related muscle diseases includes all the limb-girdle muscular dystrophies (see <related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter">Limb-Girdle Muscular Dystrophy Overview</related-object>).</p>
        <p>LGMD multi-gene panels may include testing for a number of the disorders discussed in this section. </p>
        <p>Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time; a panel may not include a specific gene of interest.</p>
        <p>Of particular note is <related-object link-type="booklink" source-id="gene" document-id="miyoshi" document-type="chapter">dysferlinopathy</related-object>, which includes a spectrum of muscle disease that is characterized by two main phenotypes: Miyoshi myopathy with primarily distal weakness and limb-girdle muscular dystrophy type 2B (LGMD2B) with primarily proximal weakness. Miyoshi myopathy (median age of onset 19 years) is characterized by muscle weakness and atrophy, most marked in the distal parts of the legs, especially the gastrocnemius and soleus muscles. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. LGMD2B is characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles in adolescence or young adulthood, with slow progression.</p>
        <p><bold>Distal myopathies.</bold> For the differential diagnosis of distal myopathies, the combination of muscle MRI, muscle pathology, and mode of inheritance is useful in reducing the need for molecular genetic diagnostics [<xref ref-type="bibr" rid="ano5-md.REF.udd.2012.5">Udd 2012</xref>].</p>
        <table-wrap id="ano5-md.T.distal_myopathies" position="anchor" orientation="portrait">
          <label>Table 3. </label>
          <caption>
            <p>Distal Myopathies</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Disease Name</th>
                <th id="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mean Age at Onset (Years)</th>
                <th id="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Initial Muscle Group Involved</th>
                <th id="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Serum Creatine Kinase Concentration</th>
                <th id="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Muscle Biopsy</th>
                <th id="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene (Locus)&#x000a0;<sup>1</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1 hd_h_ano5-md.T.distal_myopathies_1_1_1_2 hd_h_ano5-md.T.distal_myopathies_1_1_1_3 hd_h_ano5-md.T.distal_myopathies_1_1_1_4 hd_h_ano5-md.T.distal_myopathies_1_1_1_5 hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" colspan="6" align="left" scope="col" rowspan="1">
                  <bold>Autosomal dominant</bold>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Welander distal myopathy</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;40</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Distal upper limbs (finger and wrist extensors)</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">Normal or slightly increased</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Rimmed vacuoles</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">(2p13)</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="udd" document-type="chapter">Udd distal myopathy</related-object>
                </td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;35</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Anterior compartment in legs</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">&#x000b1; Rimmed vacuoles</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TTN </italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="mfm" document-type="chapter">Zaspopathy</related-object> (Markesbery-Griggs late-onset distal myopathy)</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;40</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">Vacuolar and myofibrillar myopathy</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">LDB3 </italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="mfm" document-type="chapter">Distal myotilinopathy</related-object>
                </td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;40</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Posterior &#x0003e; anterior in legs</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Slightly increased</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Vacuolar and myofibrillar</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">MYOT </italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="mpd1" document-type="chapter">Laing early-onset distal myopathy</related-object> (MPD1)</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;20</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Anterior compartment in legs and neck flexors</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal to (rarely) moderately increased</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Type 1 fiber atrophy in tibial anterior muscles; disproportion in proximal muscles</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">MYH7 </italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Distal myopathy with vocal cord and pharyngeal signs (MPD2)</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">35-60</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Asymmetric lower leg and hands; dysphonia</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1-8 times</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Rimmed vacuoles</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">MATR3</italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Distal myopathy with pes cavus and areflexia</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">15-50</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Anterior and posterior lower leg; dysphonia and dysphagia</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2-6 times</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Dystrophic, rimmed vacuoles</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">(19p13)</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">New Finnish distal myopathy (MPD3)</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;30</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Hands or anterior lower leg</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">1-4 times</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Dystrophic; rimmed vacuoles; eosinophilic inclusions</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">(8p22-q11 and 12q13-q22)</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1 hd_h_ano5-md.T.distal_myopathies_1_1_1_2 hd_h_ano5-md.T.distal_myopathies_1_1_1_3 hd_h_ano5-md.T.distal_myopathies_1_1_1_4 hd_h_ano5-md.T.distal_myopathies_1_1_1_5 hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" colspan="6" align="left" scope="col" rowspan="1">
                  <bold>Autosomal recessive</bold>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="ibm" document-type="chapter">Nonaka early-adult-onset distal myopathy</related-object>
                </td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">15-20</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Anterior compartment in legs</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;10 times</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Rimmed vacuoles</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">GNE </italic>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="miyoshi" document-type="chapter">Miyoshi early adult-onset myopathy</related-object>
                </td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Posterior compartment in legs</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;10 times</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Myopathic changes</td>
                <td headers="hd_h_ano5-md.T.distal_myopathies_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">DYSF </italic>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>
                <xref ref-type="bibr" rid="ano5-md.REF.udd.2001.561">Udd &#x00026; Griggs [2001]</xref>
              </p>
            </fn>
            <fn id="ano5-md.TF.3.1">
              <label>1. </label>
              <p>Locus given only if the gene is not known</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="ano5-md.Management">
        <title>Management</title>
        <sec id="ano5-md.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis </title>
          <p>To establish the extent of disease and needs of an individual diagnosed with <italic toggle="yes">ANO5</italic>-related muscle diseases, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic evaluation and manual muscle force measurement to establish a baseline for future assessment of disease progression and the possible need for assistive devices.</p>
            </list-item>
            <list-item>
              <p>Muscle imaging (CT or MRI) to identify the pattern of affected muscles in detail</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="ano5-md.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The need for orthoses or other assistive devices varies individually. Most patients remain ambulatory without assistance for decades.</p>
          <p>No definitive treatments for the limb-girdle muscular dystrophies exist. Management is tailored to each individual and each specific subtype. Management to prolong survival and improve quality of life includes weight control to avoid obesity, physical therapy and stretching exercises to promote mobility and prevent contractures, and use of mechanical aids to help ambulation and mobility. </p>
          <p>Hyperextension of the knee can be treated by splinting [<xref ref-type="bibr" rid="ano5-md.REF.hicks.2011.171">Hicks et al 2011</xref>].</p>
        </sec>
        <sec id="ano5-md.Surveillance">
          <title>Surveillance</title>
          <p>For persons with muscle weakness, evaluate muscle strength and functional status every six to 12 months. </p>
          <p>For asymptomatic persons, evaluate less frequently.</p>
        </sec>
        <sec id="ano5-md.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Heavy muscle force training of weak muscles should be avoided as very high levels of CK have been measured after strenuous exercise [<xref ref-type="bibr" rid="ano5-md.REF.milone.2012.13">Milone et al 2012</xref>, <xref ref-type="bibr" rid="ano5-md.REF.penttil_.2012.897">Penttil&#x000e4; et al 2012</xref>]. </p>
          <p>The use of statins, which can induce muscle pain and worsen muscle weakness, requires extra monitoring of clinical status especially at the beginning of treatment. </p>
        </sec>
        <sec id="ano5-md.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="ano5-md.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ano5-md.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="ano5-md.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ano5-md.Mode_of_Inheritance">
          <title>Mode of Inheritance </title>
          <p><italic toggle="yes">ANO5</italic>-related muscle diseases are inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="ano5-md.Risk_to_Family_Members">
          <title>Risk to Family Members </title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one mutant allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with an <italic toggle="yes">ANO5</italic>-related muscle disease are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">ANO5</italic>. </p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier. </p>
        </sec>
        <sec id="ano5-md.Carrier_Detection">
          <title>Carrier Detection </title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified. </p>
        </sec>
        <sec id="ano5-md.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues </title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="ano5-md.Prenatal_Testing">
          <title>Prenatal Testing </title>
          <p>If the <italic toggle="yes">ANO5</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p>Requests for prenatal testing for conditions which (like the <italic toggle="yes">ANO5</italic>-related muscle diseases) do not affect intellect and are typically adult onset are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">ANO5</italic> pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="ano5-md.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ano5-md.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">ANO5</italic> is predicted to produce several alternatively spliced transcripts that encode different isoforms; however, only two transcripts have been described. The major transcript variant expressed in muscle (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_213599.2">NM_213599.2</ext-link>) has 22 exons and 6661 base pairs and codes for a 913-amino acid protein (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_998764.1">NP_998764.1</ext-link>), whereas the other transcript variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001142649.1">NM_001142649.1</ext-link>) codes for a 912-amino acid product. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ano5-md" object-id="ano5-md.molgen.TA">Table A</related-object>, <bold>Gene</bold>. </p>
        <p><bold>Benign allelic variants.</bold> In exon 10, the common benign variant c.966A&#x0003e;T (dbSNP reference rs7481951) has a frequency of 35%, according to 1000 Genomes.</p>
        <p><bold>Pathogenic allelic variants.</bold> A large number of recessive <italic toggle="yes">ANO5</italic> mutations are known<italic toggle="yes">.</italic> The mutations are distributed evenly along the gene without any clear mutational hotspot. </p>
        <p>The most common mutation in European populations, c.191dupA, causes a frameshift that leads to premature truncation of the protein (p.Asn64LysfsTer15). </p>
        <p>Other small frameshift insertions and deletions include: c.1627dupA and c.2311_2312delCA.</p>
        <p>Most mutations seem to be missense mutations, like the common variant c.2272C&#x0003e;T and the rarer variants c.242A&#x0003e;G, c.692G&#x0003e;T, c.1643C&#x0003e;T, c.1733T&#x0003e;C, and c.2101A&#x0003e;G. </p>
        <p>Several mutations affect splicing (e.g., c.1295C&#x0003e;G and c.1407+5G&#x0003e;A). </p>
        <table-wrap id="ano5-md.T.selected_ano5_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 4. </label>
          <caption>
            <p>Selected <italic toggle="yes">ANO5</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Class of Variant Allele</th>
                <th id="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change </th>
                <th id="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.966A&#x0003e;T</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu322Phe</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_4" rowspan="15" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_213599.2">NM_213599.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_998764.1">NP_998764.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_1" rowspan="14" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.191dupA&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn64LysfsTer15</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.242A&#x0003e;G</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp81Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.692G&#x0003e;T</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly231Val</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1295C&#x0003e;G</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala432GlyfsTer49</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1407+5G&#x0003e;A</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Glu445_Trp469del</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1627dupA</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met543AsnfsTer11</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1643C&#x0003e;T</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr548Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1733T&#x0003e;C</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe578Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2101A&#x0003e;G</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn701Asp</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2272C&#x0003e;T&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg758Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2311_2312delCA</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln771AlafsTer8</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1066T&#x0003e;C</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys356Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1066T&#x0003e;G</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys356Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1538C&#x0003e;T</td>
                <td headers="hd_h_ano5-md.T.selected_ano5_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr513Ile</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="ano5-md.TF.4.1">
              <label>1. </label>
              <p>The most common mutations in northern European populations are c.191dupA in exon 5 and c.2272C&#x0003e;T in exon 20.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The major isoform in muscle consists of 913 amino acids. The protein anoctamin-5 has eight transmembrane domains, a re-entrant loop (a structural motif that goes only halfway through the membrane and then turns back to the side from which it originates) between the fifth and sixth transmembrane domain, and a DUF590 domain of unknown function. The function of anoctamin-5 is not known. </p>
        <p><bold>Abnormal gene product.</bold> Some pathogenic allelic variants leading to <italic toggle="yes">ANO5</italic>-related muscle diseases cause a change in one amino acid and some lead to premature truncation or aberrant splicing. How the abnormal gene products cause disease is not fully understood. </p>
      </sec>
      <sec id="ano5-md.References">
        <title>References</title>
        <sec id="ano5-md.Literature_Cited">
          <title>Literature Cited </title>
          <ref-list id="ano5-md.Literature_Cited.reflist0">
            <ref id="ano5-md.REF.bolduc.2010.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bolduc</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marlow</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boycott</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saleki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itakura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robitaille</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parent</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuta</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamata</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linssen</surname>
                    <given-names>WHJP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahjneh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Visser</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bashir</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies.</article-title>
                <source>Am J Hum Genet</source>
                <volume>86</volume>
                <fpage>213</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">20096397</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.bouquet.2012.135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bouquet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coss&#x000e9;e</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;hin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deburgrave</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leturcq</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Miyoshi-like distal myopathy with mutations in anoctamin 5 gene.</article-title>
                <source>Rev Neurol (Paris)</source>
                <volume>168</volume>
                <fpage>135</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">22336395</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.deschauer.2011.1596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joshi</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gl&#x000e4;ser</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanisch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoltenburg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zierz</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Muscular dystrophy due to mutations in anoctamin 5: clinical and molecular genetic findings.</article-title>
                <source>Nervenarzt.</source>
                <year>2011</year>
                <volume>82</volume>
                <fpage>1596</fpage>
                <lpage>603</lpage>
                <pub-id pub-id-type="pmid">21739273</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.hicks.2011.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hicks</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muelas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koehler</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huebner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barresi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eagle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polvikoski</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radunovic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krause</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laval</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lochm&#x000fc;ller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A founder mutation in anoctamin 5 is a major cause of limb-girdle muscular dystrophy.</article-title>
                <source>Brain</source>
                <volume>134</volume>
                <fpage>171</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">21186264</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.magri.2012.934">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Magri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bo</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Angelo</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sciacco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gandossini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Govoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Napoli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciscato</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fortunato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brighina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucchini</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresolin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <article-title>Frequency and characterisation of anoctamin 5 mutations in a cohort of Italian limb-girdle muscular dystrophy patients.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2012</year>
                <volume>22</volume>
                <fpage>934</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">22742934</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.mahjneh.2010.791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mahjneh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaiswal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamminen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marlow</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiuru-Enari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bashir</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A new distal myopathy with mutation in anoctamin 5.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>20</volume>
                <fpage>791</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20692837</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.marconi.2013.613">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marconi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunamonti Binello</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badiali</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caci</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusano</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garibaldi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pippucci</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhoden</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galietta</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalatta</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balbi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>A novel missense mutation in ANO5/TMEM16E is causative for gnathodiaphyseal dyplasia in a large Italian pedigree.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2013</year>
                <volume>21</volume>
                <fpage>613</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23047743</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.milone.2012.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Milone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liewluck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winder</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pianosi</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <article-title>Amyloidosis and exercise intolerance in ANO5 muscular dystrophy.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2012</year>
                <volume>22</volume>
                <fpage>13</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21820307</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.penttil_.2012.897">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Penttil&#x000e4;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmio</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suominen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raheem</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evil&#x000e4;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muelas Gomez</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tasca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waddell</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>NF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barboi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hackman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by <italic toggle="yes">ANO5</italic>.</article-title>
                <source>Neurology</source>
                <volume>78</volume>
                <fpage>897</fpage>
                <lpage>903</lpage>
                <pub-id pub-id-type="pmid">22402862</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.schessl.2012.740">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schessl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kress</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoser</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Novel <italic toggle="yes">ANO5</italic> mutations causing hyper-CK-emia, limg-girdle muscular weakness and Miyoshi type of muscular dystrophy.</article-title>
                <source>Muscle Nerve</source>
                <volume>45</volume>
                <fpage>740</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">22499103</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.tsutsumi.2004.1255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsutsumi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamata</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vokes</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruoka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakakuki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enomoto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amagasa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagayama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito-Ohara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inazawa</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moritani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaoka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itakura</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia.</article-title>
                <source>Am J Hum Genet</source>
                <volume>74</volume>
                <fpage>1255</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15124103</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.udd.2012.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Distal myopathies.</article-title>
                <source>Neuromusc Disord.</source>
                <volume>22</volume>
                <fpage>5</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">22197426</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.udd.2001.561">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>Distal myopathies.</article-title>
                <source>Curr Opin Neurol.</source>
                <year>2001</year>
                <volume>14</volume>
                <fpage>561</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11562566</pub-id>
              </element-citation>
            </ref>
            <ref id="ano5-md.REF.wahbi.2013.76">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wahbi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;hin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;cane</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leturcq</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coss&#x000e9;e</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stojkovic</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toussaint</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaxotte</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cluzel</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duboc</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Dilated cardiomyopathy in patients with mutations in anoctamin 5.</article-title>
                <source>Int J Cardiol.</source>
                <year>2013</year>
                <volume>168</volume>
                <fpage>76</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23041008</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ano5-md.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ano5-md.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>29 November 2012 (me) Review posted live </p>
            </list-item>
            <list-item>
              <p>19 July 2012 (sp) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="ano5-md.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Asymmetric atrophy of the muscles of the left calf in an individual with an <italic toggle="yes">ANO5</italic> mutation</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ano5-md-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="ano5-md.F2" orientation="portrait">
          <label>Figure 2.<break/><break/></label>
          <caption>
            <p>A. Fatty degenerative changes in posterior thigh muscles in the left vastus medialis and intermedius musclesB. Fatty degenerative changes in the medial gastrocnemius (left greater than right) and in the left soleus muscle </p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ano5-md-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
